In our current mini-series exploring emerging biotech companies with early pipelines and novel targets, we investigate some interesting approaches that are not common place. As large cap Pharmaland companies seem overly focused on hunting for the next checkpoint target, smaller biotechs are more nimbly coming up with some fresh ideas that might have solid merit down the road.
This is one of those such innovative companies.
What if there was a different approach where we can learn from the immune system’s response to a cancer? Sounds obvious and intuitive when put so baldly, yet few companies are actually doing that in practice.
What would such a process and pipeline look like?
Come and find out for yourselves – you may well be surprised because some ideas that seem crazy at first blush, could turn out to be rather useful indeed…
To learn more from our oncology coverage and get a heads up on insights emerging our latest analysis and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.
We get to chat with many leading oncologists and cancer researchers on Biotech Strategy Blog – it’s truly one of the perks of the job to meet experts and hear them discuss their early research.
Like a tutorial, we have the opportunity to ask questions and improve our own understanding, but where it becomes really interesting is when they talk about promising translational opportunities, because this is what we are about.
How do you translate basic research into oncology new products and figure out where are the viable opportunities?
In this post, we spoke with one of the world’s leading immunologists – someone we’ve never spoken to before – who a few weeks ago spun-out a company to commercialize one of their early research areas and while we were doing the interview told us about another commercial opportunity they had in mind. This was very much “under the radar” and in a relatively earlier stage of commercialization. Both targets have potential for synergy in our view, particularly in combination strategies and cancer immunotherapy regimens.
With one company in stealth mode and the other only incorporated a matter of weeks ago (at time of writing they don’t yet have a website), it’s exciting to see science translation in action.
This is one of the reasons why one of the many tribes that read BSB are those in business development and licensing (BD&L) or investment roles.
In this post we interviewed the delightful Prof. Akiko Iwasaki from Yale. We’ve also put together commentary on the opportunities and the science behind them, as well as some recent anecdotes gleaned from another expert in one of the fields discussed.
If you are part of a BD&L team then do consider purchasing a group or team license. We’d be happy to have our group sales department discuss this further with you.
To learn more from our oncology coverage and get a heads up on our latest analysis, commentary, and an expert interview with a leading immunologist, subscribers can log-in or you can click to gain access to BSB Premium Content.
To be successful as a cancer immunotherapy company, you not only have to be science driven (that’s a given) and offer an approach that could make a difference, you also need a vision and the ability to execute ahead of competitors in a fast moving and competitive landscape.
Dr John Beadle
We’re continuing our series on emerging cancer immunotherapy companies with an in-depth look at PsiOxus, and the vision of CEO Dr John Beadle (pictured right) for it to be a world-leading immuno-oncolytic virus company.
PsiOxus is based just outside of Oxford – it’s part of the so-called “golden triangle,” the area between London, Oxford and Cambridge in the South of England that is a driver of UK science and innovation.
The company is located in a nondescript business park 45 minutes by train from Paddington to Didcot Parkway, followed by a taxi or bus ride. You have to want to make the trip from London!
Dr Beadle kindly spoke to BSB about the competitive advantage the PsiOxus oncolytic virus platform offers, their path-to-market strategy and how he sees the company developing in the future.
With clinical data due in 2017, PsiOxus is a cancer immunotherapy company to watch out for.
Part 1 of the interview focuses on the scientific platform and cancer new products in development that are driving the company forward.
Subscribers can login to read more or you can purchase access.